Literature DB >> 18992612

Epidemiology, clinical staging, and presentation of renal cell carcinoma.

G Joel Decastro1, James M McKiernan.   

Abstract

The increasing incidence of renal cell carcinoma over the past 2 decades can be partly explained by the expanding use of abdominal imaging. As a result, the most incident renal cancers today are small, localized, and asymptomatic. However, the well-documented rise in all stages of RCC calls into question the nature of these asymptomatic lesions. The expected "screening effect" of detecting RCC when it is small and localized, with subsequent decreases in disease-specific mortality, has not been observed. Disease-specific mortality is actually rising, especially in African American patients. Effective interventions aimed at reducing obesity, hypertension, and smoking may help in reducing the incidence of RCC in the future.

Entities:  

Mesh:

Year:  2008        PMID: 18992612     DOI: 10.1016/j.ucl.2008.07.005

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  49 in total

Review 1.  Dual energy MDCT assessment of renal lesions: an overview.

Authors:  Achille Mileto; Daniele Marin; Rendon C Nelson; Giorgio Ascenti; Daniel T Boll
Journal:  Eur Radiol       Date:  2013-10-04       Impact factor: 5.315

2.  Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.

Authors:  Xiaolong Zhang; Xiaopeng Zhang; Tianbao Huang; Jiang Geng; Min Liu; Junhua Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Hydrogen sulfide treatment ameliorates long-term renal dysfunction resulting from prolonged warm renal ischemia-reperfusion injury.

Authors:  Ian Lobb; Justin Zhu; Weihua Liu; Aaron Haig; Zhu Lan; Alp Sener
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

4.  Association of genetic variations in RTN4 3'-UTR with risk for clear cell renal cell carcinoma.

Authors:  Yan Pu; Peng Chen; Bin Zhou; Peng Zhang; Yanyun Wang; Yaping Song; Lin Zhang
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

Review 5.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

6.  Evaluation of Urine Aquaporin-1 and Perilipin-2 Concentrations as Biomarkers to Screen for Renal Cell Carcinoma: A Prospective Cohort Study.

Authors:  Jeremiah J Morrissey; Vincent M Mellnick; Jingqin Luo; Marilyn J Siegel; R Sherburne Figenshau; Sam Bhayani; Evan D Kharasch
Journal:  JAMA Oncol       Date:  2015-05       Impact factor: 31.777

Review 7.  Therapeutic effects and associated adverse events of first-line treatments of advanced renal cell carcinoma (RCC): a meta-analysis.

Authors:  Lei Wang; Ling Ma; Xinli Wang; Bing Li; Shan Guo; Qingdong Qiao
Journal:  Int Urol Nephrol       Date:  2015-02-17       Impact factor: 2.370

8.  Severe blood loss anaemia and recurrent intussusceptions as first presentation of bowel metastatic renal cell carcinoma: A case report and review of the literature.

Authors:  Claudia Trojaniello; Maria Giuseppa Vitale; Biagio Trojaniello; Maria Luisa Lentini Graziano; Mariarosa Coccaro; Giacomo Cartenì; Vincenzo Montesarchio
Journal:  Mol Clin Oncol       Date:  2017-08-07

9.  Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade.

Authors:  Jeremiah J Morrissey; Jonathan Mobley; Joseph Song; Joel Vetter; Jingqin Luo; Sam Bhayani; R Sherburne Figenshau; Evan D Kharasch
Journal:  Urology       Date:  2013-11-13       Impact factor: 2.649

10.  Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma.

Authors:  Guihua Wang; Lianhua Chen; Junsong Meng; Min Chen; Ling Zhuang; Liqin Zhang
Journal:  Int Urol Nephrol       Date:  2013-02-03       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.